Samsung Biologics

Samsung Biologics is engaged in the manufacture of biological products. Co. provides CMO (Contract Manufacturing Organization) services that serve other domestic and international pharmaceutical companies on a contract basis to produce high-tech biomedicine as of the date when the business report is submitted. also engages in the research & development and commercialization of biosimilar products.
  • Ticker207940
  • ISINKR7207940008
  • ExchangeKorea Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountrySouth Korea


Samsung Biologics Co Ltd: 3 directors sold

Three Directors at Samsung Biologics Co Ltd sold 1,900 shares at between 510,000.000KRW and 521,333.333KRW. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricte...

Dominic Rose ...
  • Naresh Chouhan

Global CDMOs - Impact of Alzheimer's Windfall

Our unique coverage of the biggest CDMO’s allows us to quantify the financial impact on the industry of a potential Alzheimer’s windfall from Biogen’s aducanumab. As the FDA filing draws closer, Biogen are likely to be involved in intense negotiations to find alternative sources of supply. Our highly detailed analysis shows how much aducanumab will need to be produced, who the winners are likely to be, the revenue uplift they may enjoy and the NPV uplift to each player. Lonza & Samsung Biologics are likely the biggest winners with Catalent close behind.

With a more favourable environment, SAMSUNG BIOLOGICS CTD. improves to Positive

SAMSUNG BIOLOGICS CTD. (KR), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date January 10, 2020, the closing price was KRW 436,500.00 and its potential was estimated at KRW 472,097.15.

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

Samsung Biologics (207940.KS): Q18 preview, look from a long-term perspective

- We maintain BUY on Samsung BioLogics given the prospect of rising biologics CMO demand in the mid/long term and the expected normalization of its plant 3 facility in 4Q18. We adjust up our target price from KRW510,000 to KRW680,000 considering the following: 1) global biologics CMO/biosimilar peer multiples remain high; 2) subsidiary Samsung Bioepis’s key pipeline drug obtained a European sales license; and 3) the value of SAIT101 developed by Archigen Biotech, its JV with AstraZeneca, has been recognized into our valuation.